1. |
Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA Oncol, 2019, 5(4): 546-550.
|
2. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
|
3. |
Aquino JL, Said MM, Pereira DA, et al. Complications of the rescue esophagectomy in advanced esophageal cancer. Arq Bras Cir Dig, 2013, 26(3): 173-178.
|
4. |
Jiao R, Luo H, Xu W, et al. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: Progress and opportunities. Onco Targets Ther, 2019, 12: 6023-6032.
|
5. |
Baba Y, Nomoto D, Okadome K, et al. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci, 2020, 111(9): 3132-3141.
|
6. |
Manson G, Norwood J, Marabelle A, et al. Biomarkers associated with checkpoint inhibitors. Ann Oncol, 2016, 27(7): 1199-1206.
|
7. |
Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol, 2016, 13(4): 228-241.
|
8. |
Mantovani A, Marchesi F, Malesci A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol, 2017, 14(7): 399-416.
|
9. |
Porta C, Sica A, Riboldi E. Tumor-associated myeloid cells: New understandings on their metabolic regulation and their influence in cancer immunotherapy. FEBS J, 2018, 285(4): 717-733.
|
10. |
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462(7269): 108-112.
|
11. |
Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 2016, 17(1): 218.
|
12. |
Geeleher P, Cox N, Huang RS. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One, 2014, 9(9): e107468.
|
13. |
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun, 2019, 10(1): 1523.
|
14. |
Cheng YF, Chen HS, Wu SC, et al. Esophageal squamous cell carcinoma and prognosis in Taiwan. Cancer Med, 2018, 7(9): 4193-4201.
|
15. |
Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: Chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol, 2019, 49(5): 412-420.
|
16. |
Hu X, Wu D, He X, et al. circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol Cancer, 2019, 18(1): 160.
|
17. |
Kojima T, Shah MA, Muro K, et al. Randomized phaseⅢKEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol, 2020, 38(35): 4138-4148.
|
18. |
Zhang J, Shi Z, Xu X, et al. The influence of microenvironment on tumor immunotherapy. FEBS J, 2019, 286(21): 4160-4175.
|
19. |
Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature, 2013, 501(7466): 252-256.
|
20. |
Overacre-Delgoffe AE, Chikina M, Dadey RE, et al. Interferon-γ drives Treg fragility to promote anti-tumor immunity. Cell, 2017, 169(6): 1130-1141.
|
21. |
Liu C, Somasundaram A, Manne S, et al. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. Nat Immunol, 2020, 21(9): 1010-1021.
|
22. |
Iwata R, Hyoung Lee J, Hayashi M, et al. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma. Neuro Oncol, 2020, 22(3): 333-344.
|
23. |
Janakiram M, Shah UA, Liu W, et al. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev, 2017, 276(1): 26-39.
|
24. |
Flajnik MF, Tlapakova T, Criscitiello MF, et al. Evolution of the B7 family: Co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics, 2012, 64(8): 571-590.
|
25. |
Xiao Y, Freeman GJ. A new B7: CD28 family checkpoint target for cancer immunotherapy: HHLA2. Clin Cancer Res, 2015, 21(10): 2201-2203.
|
26. |
Boor PPC, Sideras K, Biermann K, et al. HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. Br J Cancer, 2020, 122(8): 1211-1218.
|
27. |
Xu G, Shi Y, Ling X, et al. HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer. Cancer Cell Int, 2021, 21(1): 252.
|
28. |
Zhou QH, Li KW, Chen X, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer, 2020, 8(1): e000157.
|
29. |
Ge PL, Li SF, Wang WW, et al. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma. Aging (Albany NY), 2020, 12(6): 5479-5499.
|
30. |
Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013, 4: 2612.
|
31. |
Zhang C, Cheng W, Ren X, et al. Tumor purity as an underlying key factor in glioma. Clin Cancer Res, 2017, 23(20): 6279-6291.
|
32. |
Mao Y, Feng Q, Zheng P, et al. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Manag Res, 2018, 10: 3569-3577.
|